**Hanke 2018**  [Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil and digoxin. CPT: Pharmacometrics & Systems Pharmacology (2018)](https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/psp4.12343)

**Hohmann 2015** [Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol (2015)](https://doi.org/10.1111/bcp.12502)

**Hyland 2009** [Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, Jones B. In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol (2009)](https://doi.org/10.1111/j.1365-2125.2009.03386.x)

**Thummel 1996** [Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther (1996)](https://doi.org/10.1016/S0009-9236(96)90177-0)

**OSP Database** [https://github.com/Open-Systems-Pharmacology/Database-for-observed-data](https://github.com/Open-Systems-Pharmacology/Database-for-observed-data)

